CDK8 inhibitor

SI-7887

CDK8 inhibitor, >98% (HPLC)

IUPAC Name : 3-Methyl-5-(5-methyl-4-(4-(trifluoromethyl)benzyl)-4H-1,2,4-triazol-3-yl)-1H-indazole

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : This is an optimized azaindole CDK8 inhibitor developed through a structure‑guided generative chemistry campaign, achieving improved microsomal stability, kinase selectivity, and cross‑species pharmacokinetics. It shows strong CDK8 target engagement and delivers robust tumor growth inhibition across multiple in vivo models following oral dosing, positioning it as a potent, orally active CDK8‑targeted anticancer lead.

References : Li Y. et al.: J. Med. Chem., 66(8), 5439-545, 2023.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.